BBNX

Beta Bionics

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Medical Devices

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

04/21/26

Business Summary

Beta Bionics operates in the medical device space, developing specialized therapeutic systems aimed at chronic disease management. The company generates cash through device sales and likely recurring revenue streams tied to consumables or system usage, typical of medical technology platforms. Its moat, if realized, would stem from regulatory approvals, clinical validation, and integration into physician workflows that create switching costs. In medical devices, once embedded in treatment protocols, products can benefit from reimbursement alignment and patient ecosystem lock-in, but sustainable cash generation ultimately depends on scaling manufacturing while converting operating losses into durable margins.

VALUATION

P/E

-

Market Cap ($M USD)

$393

Forward P/E

-

PEG

-

PRICE TO SALES

3.6

PRICE TO BOOK

1.4

EV / EBITDA

-2.6

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.81

Next Year EPS Growth Estimate

-$1.94

Next Year Revenue Growth Estimate

34.80%

Return on Equity (ROE)

-25.40%

Operating Margin

-71.50%

Debt-to-Equity

0

Piotroski F-Score

5

Altman Z-Score

4.6

Return on Invested Capital (ROIC)

-296.20%%

Current Ratio

8.7

Quick Ratio

Gainseekers Quantitative Analysis

Summary

BBNX is a speculative, balance-sheet-stable but economically broken small-cap trading at a $393M market cap with no earnings, no forward P/E, and deeply negative profitability metrics. The absence of a P/E and PEG reflects continued losses, with EPS at -2.6 and next year still projected at -$1.81, meaning this is not a near-term earnings recovery story. However, the Altman Z-Score of 4.6 and a massive 8.7 current ratio signal very low bankruptcy risk despite operating losses, creating a paradox: financially safe, but operationally unproven. At 3.6x sales and 1.4x book, the stock is not distressed-cheap, yet it is priced like a high-risk turnaround with no margin cushion. This is not mispriced for growth; it is priced for survival with optionality.

AI Exposure / Tech Reliance

As a Medical Devices company in Healthcare, BBNX operates in a sector inherently aligned with advanced automation, AI-enabled diagnostics, and data-driven therapeutic optimization. The industry naturally integrates connected devices and algorithmic treatment personalization, which can enhance product stickiness and reimbursement defensibility. However, the financial profile suggests the company is still in a heavy investment phase rather than monetizing technological leverage at scale.

The Bull Case

A value-oriented GARP investor could argue that the balance sheet strength is the hidden asset here. A current ratio of 8.7 and an Altman Z-Score of 4.6 indicate exceptional liquidity and low financial distress risk, giving management time to execute. The Piotroski F-Score of 5 suggests middling but not collapsing fundamentals—this is not a zero. Despite an operating margin of -25.40% and ROIC of -296.20%, the forward EPS improvement from -2.6 to -$1.81 implies narrowing losses, which, if sustained, could drive significant operating leverage. Trading at 1.4x book and 3.6x sales, the valuation embeds skepticism, so even modest margin normalization could re-rate the equity sharply.

The Bear Case

The structural problems are serious. Operating margin at -25.40% and ROIC at -296.20% signal catastrophic capital inefficiency—this business is destroying value on every dollar invested. Debt/Equity at -71.50% suggests an unusual capital structure dynamic that distorts traditional leverage interpretation, but combined with negative earnings and no defined PEG or forward P/E, visibility into scalable profitability is nonexistent. Sales Growth Next Year listed as -$1.94 adds another layer of concern, implying either contraction or forecasting instability. With EPS still negative next year and no dividend support, investors are underwriting execution risk without proof of economic viability.

Market Sentiment & Smart Money

Short Interest %

17.80%

Analyst Consensus

1.62

Average Analyst Price Target

$23.33

Institutional Ownership %

109.70%

1-Year Beta

1.12

Insider Buying % (6 Mo)

2.30%%

Distance to 52-Week High

27.10%%

Distance to 52-Week Low

100.70%%